Skip to main content
Publications
Duran CE, Riera-Arnau J, Abtahi S, Pajouheshnia R , Hoxhaj V, Gamba M, Alsina E, Martin-Perez M, Garcia-Posa P, Llorente-Garcia A, Gonzalez-Bermejo D, Ibanez L, Sabate M, Vidal X, Ballarin E, Sanfelix-Gimeno G, Rodriguez-Bernal C, Peiro S, Garcia-Sempere A, Sanchez-Saez F, Lentile V, Ingrasciotta Y, Guarneri C, Tanaglia M, Tari M, Herings R, Houben E, Swart-Polinder K, Holthuis E, Huerta C, Gini R, Roberto G, Bartolini C, Paoletti O, Limoncella G, Girardi A, Hyeraci G, Andersen M, Kristiansen SB, Hallgreen CE, Klungel O, Sturkenboom M. Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis . Front Pharmacol. 2023 Aug 17;14:1207976. doi: 10.3389/fphar.2023.1207976
Abdulkareem NM, Bhat R, Powell RT, Chikermane S, Yande S , Trinh L, Abdelnasser HY, Tabassum M, Ruiz A, Sobieski M, Nguyen ND, Johnson M, Kaipparettu BA, Johnson CA, Bond RA, Stephan C, Triveni MV. Screening of GPCR drugs for repurposing in breast cancer . Front Pharmacol. 2022 Dec 6;13:1049640. doi: 10.3389/fphar.2022.1049640
Goyal RK , Cuyun Carter G, Nagar SP , Nash Smyth E, Price GL, Parikh RC , Huang YJ, Li L, Davis KL , Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States . Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871